Precision nanomedicine to treat non-small cell lung cancer
Open Access
- 10 April 2024
- journal article
- research article
- Published by Elsevier in Life Sciences
- Vol. 346, 122614
Abstract
No abstract availableKeywords
Funding Information
- Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education
- Manipal Academy of Higher Education
This publication has 131 references indexed in Scilit:
- Nano-mediated strategy for targeting and treatment of non-small cell lung cancer (NSCLC)Naunyn-Schmiedeberg's Archives of Pharmacology, 2023
- Selpercatinib: A Review in Advanced RET Fusion-Positive NSCLCTargeted Oncology, 2022
- Targeted Drug/Gene/Photodynamic Therapy via a Stimuli‐Responsive Dendritic‐Polymer‐Based Nanococktail for Treatment of EGFR‐TKI‐Resistant Non‐Small‐Cell Lung CancerAdvanced Materials, 2022
- Pralsetinib: A Review in Advanced RET Fusion-Positive NSCLCDrugs, 2022
- Pulmonary delivery of osimertinib liposomes for non-small cell lung cancer treatment: formulation development and in vitro evaluationDrug Delivery and Translational Research, 2021
- Clinicopathologic, genomic and protein expression characterization of 356ROS1fusion driven solid tumors casesInternational Journal of Cancer, 2020
- Advances in targeting EGFR allosteric site as anti-NSCLC therapy to overcome the drug resistancePharmacological Reports, 2020
- Near-infrared/pH dual-responsive nanocomplexes for targeted imaging and chemo/gene/photothermal tri-therapies of non-small cell lung cancerActa Biomaterialia, 2020
- DNA adducts: Formation, biological effects, and new biospecimens for mass spectrometric measurements in humansMass Spectrometry Reviews, 2018
- Neurotrophin signaling: many exciting surprises!Cellular and Molecular Life Sciences, 2006